Membranous glomerulonephritis diagnostic study of choice

	Membranous glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranous glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
Ultrasound
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranous glomerulonephritis diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranous glomerulonephritis diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranous glomerulonephritis diagnostic study of choice
CDC on Membranous glomerulonephritis diagnostic study of choice
Membranous glomerulonephritis diagnostic study of choice in the news
Blogs on Membranous glomerulonephritis diagnostic study of choice
Directions to Hospitals Treating Membranous glomerulonephritis
Risk calculators and risk factors for Membranous glomerulonephritis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Ahsan Hussain, M.D.[2]

Overview

- The most efficient ans sensitive test is ANA, ds-DNA antibodies specific test that is utilized for diagnosis of membranous glomerulonephritis.
- The gold standard test for the diagnosis of biopsy.

Biopsy is the gold standard test for the diagnosis of membranous glomerulonephritis. ^[1] ^[2] ^[1]

The complete blood count, urinalysis, 24 hour urine collection should be performed when:
- The patient presented with signs of proteinurea and hypertension.
- A positive [test] is detected in the patient.
Biopsy is the gold standard test for the diagnosis of membranous glomerulonephritis.

Biopsy is confirmatory of membranous glomerulonephritis.

The urinalysis and comprehensive chemistry panel should be performed when:

The patient presented with signs of hypertension and proteinurea.
A positive ANA, anti dsDNA is detected in the patient, to confirm the diagnosis.

There are no established criteria for the diagnosis of membranous glomerulonephritis.

↑ ^1.0 ^1.1 Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF (October 2012). "Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy". J. Am. Soc. Nephrol. 23 (10): 1735–43. doi:10.1681/ASN.2012030242. PMC 3458465. PMID 22956816.
↑ Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (June 2011). "Anti-phospholipase A2 receptor antibody in membranous nephropathy". J. Am. Soc. Nephrol. 22 (6): 1137–43. doi:10.1681/ASN.2010090967. PMC 3103733. PMID 21566055.
↑ Timmermans SA, Ayalon R, van Paassen P, Beck LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW (December 2013). "Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy". Am. J. Kidney Dis. 62 (6): 1223–5. doi:10.1053/j.ajkd.2013.07.019. PMID 24021909.
↑ De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (February 2017). "A Proposal for a Serology-Based Approach to Membranous Nephropathy". J. Am. Soc. Nephrol. 28 (2): 421–430. doi:10.1681/ASN.2016070776. PMC 5280030. PMID 27777266.